Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 10/02/2023
NCI Pipeline News


In this edition of the DCTD newsletter, Brian Sorg, PhD, branch chief of the Cancer Diagnosis Program’s (CDP) Diagnostic Biomarkers and Technology Branch (DBTB), describes how he landed in the field of biomedical engineering and the latest in diagnostic technology.

How did you end up becoming a biomedical engineer?

Growing up, I always liked math and science, and biology was my favorite subject in high school. When I got to college, I planned to major in biology, graduate, and find a job; however, I noticed that engineering degrees had really good job prospects. I felt bad leaving biology behind, but I decided to major in electrical engineering. During college I had two summer research jobs in microbiology at the University of Maryland, where I worked in the laboratory of a family friend who was a professor, and partnered with a graduate student who helped me think about my options after college. My professor friend gave me the idea to take an electrical engineering class at Maryland with one of his faculty friends that focused on artificial and biological neural networks. That class really influenced me — I liked being able to combine biology and engineering, so I decided to go to graduate school for a masters’ degree in biomedical engineering.

During my early years of graduate school, I worked in a lab studying the biophysical properties of the motor protein kinesin. I built and used an apparatus called optical tweezers for optical trappings, where you can grab particles with a laser beam and place them on kinesin on microtubules. That work was interesting, but I wanted to do something more clinically applied, so I decided to pursue a PhD in a topic related to biomedical optics. I found programs in Texas that focused on biomedical engineering and biomedical optics that were clinically related, like imaging, ablation, and detection methods that used lasers. I continued in this research area in my post-doctoral years, and I worked on optical measurements of oxygen transport to tissue. My post-doc lab wanted to develop an imaging method to measure tumor oxygenation, so I set up a microscopy system using hyperspectral imaging of hemoglobin saturation in tumor microvasculature. This work satisfied three things that I liked scientifically — pure biology, math and statistics, and engineering. I had access to so much variety in this research, and I was able to constantly move back and forth between each discipline.

After my post-doctoral work, I started my own lab at the University of Florida in biomedical engineering. I liked academia and being directly involved in student growth, but it was hard to be the manager and give up working in the lab. Also, I really liked writing papers on my academic work, but I wasn’t so fond of writing grants. Grant writing was a good experience for me though, because now I can appreciate what grantees experience when they write their grants. At NCI, I work with principal investigators, and I really understand their position.

I’ve been at NCI for 11 years, and all those years with CDP/DBTB. When I joined DBTB, Dr. Jim Tricoli was the branch chief, and there were only two people in the branch. I’ve taken over the branch chief position after Dr. Tricoli’s recent retirement, and we are trying to build up the number of staff in the branch. I was a program director before my role as branch chief, and I still have a grant portfolio because I’d like to stay connected to the science and the grants process considering that our branch has between 150-175 active grants.

What are some highlights from the diagnostics/technology world in the last ten years?

Over the last decade we’ve seen great trends in biosensors, in vitro imaging, and cellular and molecular analysis. Spatial resolution has increased, and various -omics measurements can now be done at the individual cell level. Also, with multiplexing you can visualize multiple kinds and increasing numbers of molecules with increased resolution. Since the technology related to single-cell profiling and imaging has progressed, now we can collect data for the molecular profile plus all the molecules and cell positions relative to each other. So much data are generated, and we need new ways to handle it all. We saw artificial intelligence (AI) entering this research field several years ago, but now it has exploded. AI is everywhere in optics because it is useful to handle vast quantities of data and simplify optical hardware designs. I see CDP grantees interested in using AI as subcomponents of their work. We’re still working through how we can use AI in medicine; there is still a long way to go in the medical field.

What do you see on the horizon in cancer diagnostic research?

Investigators are really interested now in making technology smaller, more efficient, and more affordable. One example is to move technology out of large medical center labs and into the community and make it useable by people who would not usually have specific training. For example, there is interest in integrating technology into smartphones to allow the point-of-care to be at home. This was happening pre-COVID, but the increase in telemedicine due to COVID has accelerated this trend.

Another area that has strong research interest is tissue chips. As a program director in CDP, I was involved with a National Center for Advancing Translational Sciences (NCATS) collaboration. The research focused on developing a model of breast cancer metastasis to the liver. The models involved studying ‘cancer on a chip’ to show how the breast cancer cells behaved clinically: the dormant cells escaped treatment. I’ve also worked with NASA to develop tissue chips, and the pharma industry is interested in using tissue chips through the drug development process. Clinical trials are expensive and time consuming, and early preclinical data from animal models do not always translate to humans. Therefore, it would be helpful to have data using human tissue chips first. One goal of my work with NCATS is to try to propel this field forward by bringing FDA and industry partners together. I am speaking with staff from other DCTD programs about how we might create tissue chip initiatives that are focused on cancer. Toxicity studies might be the easiest thing to do first on a chip because many therapeutic compounds are toxic. It would be powerful to accurately show toxicity of anti-cancer agents early in the research process — this would save time and money.

Dr. Sorg’s research interests and NCI grant portfolio are focused on technology development for biosensors and various cellular and molecular separation and analysis techniques for biomarker discovery and clinical application. His portfolio and research interests also include liquid biopsies, microfluidics, tissue chips, in vitro optical imaging, and other biophotonics technologies for applications in cancer diagnosis and treatment.

SPOTLIGHT: NCI Updates the NCI-60 Human Tumor Cell Lines Screen

NCI has modernized the methodology for the NCI-60 to a high throughput screen, which includes a change from 96-well to 384-well plates. The NCI-60 has been an integral, free research resource for anti-cancer drug discovery and development investigators for more than 30 years, with more than 110,000 total compounds screened in 260,000 assays.

The results of this update include improved operational efficiency and methodology that is now aligned with the standard screening technology being used in the field (e.g., automated high-throughput assay in 384-well plates).

Read more about the NCI-60 and this important methodology update. Email DTP staff with questions:

September 30, 2023 was the last day to submit compounds for testing using the traditional platform. Compounds submitted after this date are being tested in the modernized NCI-60 HTS384 screen.

SPOTLIGHT — NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) Work with Moonshot Projects

The NCTN biobanks are a unique resource for well-annotated biospecimens collected during cancer clinical trials for use in research and for biomarker discovery with a goal to advance cancer treatment.

When individuals with cancer participate in clinical trials, their tumor biospecimens may be analyzed as part of the trial’s research objectives. These biospecimen studies are a critical component of research to advance cancer therapy.

As an integral part of the NCTN, the NCTN Biobanks collect, process, and store well-annotated biospecimens from the NCTN phase 3 and phase 2 trials, and some early phase trials. NCTN biospecimens have associated clinical and outcome data, which enhance the value of this unique resource. The Pathology Investigation and Resources Branch of the Cancer Diagnosis Program manages one pediatric and four adult biobanks, which received NCTN biobanking U24 grants (RFA-CA-20-002).

The demand for well-annotated legacy biospecimens for secondary research studies is steadily increasing in scale and scope. Launched through the Cancer Moonshot and funded by the 21st Century Cures Act, the Moonshot Molecular Profiling to Predict Response to Treatment Initiative (MP2PRT) awarded seven contracts to the COG and NRG NCTN biobanks between 2020-2022. The following five publications describe results stemming from the COG Biobank projects.

Publication Title/Link to Paper Highlight
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study (Gadd; 2022) Early and late samples in primary-relapse Wilms tumor pairs had different mutations
The following four publications from members of the COG Soft Tissue Sarcoma Committee showcase the importance of well-annotated biospecimens to possible improvements in disease classification, treatment decisions, and outcomes.
TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report ( Fair; 2023) Frequency of TP53 germline pathogenic variants in anaplastic rhabdomyosarcoma and the genetic factors associated with this type of sarcoma
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group ( Martin-Giacalone; 2023) Germline genetic variants and their effect on the outcomes of pediatric rhabdomyosarcoma patients
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report from the Children's Oncology Group ( Abbou; 2023) Significance of analyzing circulating tumor DNA in intermediate-risk rhabdomyosarcoma cases
Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction ( Zhang; 2022) Deep learning techniques and analysis of pathology images of rhabdomyosarcoma

The NCTN biobanks are committed to providing access to biospecimens for researchers for other secondary studies both within and outside the NCTN. It is essential that scientists from the broader translational cancer research community can search for and access NCTN legacy biospecimens and associated data. The NCTN Navigator External Link provides this service with its comprehensive, user-friendly, searchable database designed to improve access to biospecimens and data collected from NCTN cancer treatment trials. Following a transparent application and scientific merit review process, the NCTN Core Correlative Science Committee approves proposals so that researchers from the broader scientific community can receive NCTN biospecimens for critical studies aimed at advancing cancer treatments. Researchers can also contact the NCTN Groups to inquire about available biospecimens when the NCTN Navigator does not include a specific trial of interest. Learn more about the NCTN Biobanks and how to request biospecimens. External Link

DCTD Diversity, Equity, Inclusion, and Accessibility (DEIA) Update


Since our May update, DCTD has implemented two new DEIA initiatives to support staff in their professional development and to ensure equitable access to career enhancement opportunities. These initiatives included the following:

  • Launching the DCTD Individual Development Plan (IDP) (a tool for DCTD employees to explore relevant training opportunities and map out professional goals, either independently or with support from their supervisor)
  • Collaborating with the DCTD Administrative Resource Center (ARC) to develop new benchmark procedures for GS-15 Health Scientist Administrator (601) positions

We also continue to make substantial efforts in the following areas:

  • Highlighting staff contributions to the NCI mission and participation in commemorative months recognized by NIH, which celebrate the backgrounds, experiences, and heritage of staff
  • Collaborating with the NCI Equity and Inclusion Program Working Group 3 to develop an NCI hiring best practices toolkit/training as well as formal recommendations to improve operational efficiencies in the NCI hiring process
  • Convening regular DEIA meetings with DCTD leadership and the ARC to assess the workplace climate, evaluate recruitment/hiring procedures, identify areas for improvement, and create new programs
  • Broad and targeted outreach to underrepresented groups regarding all DCTD job openings

Please visit DCTD’s DEIA webpage for additional resources.

Staff Commemorative Month Celebrations

Following our DCTD celebration of Black History Month, we are delighted to introduce a new feature in our newsletter, where we recognize commemorative months celebrated by DHHS/NIH and highlight commemorative month activities. In this current feature, we are pleased to recognize Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month and LGBTQ+ Pride Month.

AANHPI Heritage Month

The month of May commemorates Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month. Originating as a 10-day celebration in 1977, the official designation of May as AAPI (or AANHPI) Heritage Month was signed into law in 1992. May was chosen to observe AANHPI Heritage Month, given that the first Japanese immigrant, Nakahama Manjirō, arrived in the United States on May 7, 1843, and May 10, 1869 marked the completion of the Transcontinental Railroad built by 15,000 to 20,000 Chinese laborers.

In this newsletter, we are pleased to highlight the AANHPI Heritage Month activities of NIH’s Asian American, Native Hawaiian, and Pacific Islander Health Scientific Interest Group (AANHPI-HSIG) founded by DCTD’s Dan Xi, PhD of OCCAM. NIH established the AANHPI-HSIG in April 2021 to advance NIH’s mission of improving the health and well-being for AA and NHPI. On May 4-5, 2022, DCTD sponsored and the NIH AANHPI-HSIG hosted the inaugural " Annual NIH AA and NHPI Health Research Conference" (Xi, 2022).

Annual NIH Asian American, Native Hawaiian, and Pacific Islander Health Research Conference, May 3-4, 2023

As the founding chair of the AANHPI-HSIG, Dr. Xi led an NIH/HHS-wide planning committee to host the second annual AANHPI Health Research Conference. DCTD sponsored this conference as well, which was held virtually on May 3-4, 2023 with more than 300 registrants. The objectives were to celebrate AANHPI heritage, highlight research and AANHPI scientists’ achievements, and discuss health research needs in the community. The theme was “Improving the Health of AA and NHPI: Risk factors, Genetic ancestry, and Disease mechanisms.” Several members of NIH senior leadership gave opening remarks, followed by four scientific sessions. The NIH Record recently highlighted this event. The conference continued to provide recommendations for the National Strategy of the White House Initiative on AANHPI and the HHS Priority Goal 5 to “Strengthen Asian American, Native Hawaiian, and Pacific Islander Health Research” contributed by NIH AANHPI-HSIG-led initiatives.

Dan Xi, PhD

Reflecting on AANHPI Heritage Month and the conference, Dr. Xi shares, “As an Asian American and chair of the NIH AANHPI-HSIG, I am deeply appreciative of the bipartisan support Reflecting on AANHPI Heritage Month and the conference, Dr. Xi shares, “As an Asian American and chair of the NIH AANHPI-HSIG, I am deeply appreciative of the bipartisan support given to the AA and NHPI community, such as Congress’ designation of May as Asian American and Pacific Islander (AAPI) Heritage Month in 1992, the White House establishment of the inaugural Initiative on AAPI in 1999, and its reinstatement in 2021. The annual heritage month celebrates that AA and NHPIs have enriched America's history and instrumentally contributed to the success of America. I greatly appreciate the support of DCTD, NCI, and NIH. Though a lot still needs to be done and many challenges remain, it is encouraging to see that advancing equity through strengthening research on health and well-being of AA a nd NHPI is making progress at NCI and NIH. I am greatly honored and proud to contribute to this beyond the regular duties of my job through leading the AANHPI-HSIG and the annual AANHPI health conference commemorating the May heritage month.”

LGBTQ+ Pride Month

LGBTQ+ Pride Month is commemorated in June in remembrance of the Stonewall Uprising of 1969. Stonewall was a series of protests by members of the LGBTQ+ community in response to police violence and raiding of the New York City Stonewall Inn on June 28, 1969. Originating as Gay and Lesbian Pride Month in 1999, Pride Month was officially expanded to include all members of the LGBTQ+ community in 2011.

Celebrations of LGBTQ+ Pride Month were held at NIH where, for the first time, the Transgender Flag was raised during an event hosted by The Office of Equity, Diversity, and Inclusion’s (EDI) Sexual and Gender Minority Engagement Committee, along with Salutaris and the NIH SGM Employee Resource Group. An EDI feature on the evolution of the Pride Flag as well as blog posts on the meaning of the Transgender Flag and creating safe spaces can be found on the EDI website.

'Seeing the Transgender Flag fly at NIH on our day of visibility makes me feel safe, supported, and protected like nothing else. It is an unequivocal statement that we are a united community.' -Willow, MSW, Program Analyst, NIH Sexual & Gender Minority Research Office

(Images and Quote from Twitter/X: @NIH_EDI) External Link

Messages from NIH leadership honored the experiences of LGBTQ+ communities as well as NIH’s efforts to increase inclusion and reduce health disparities within LGBTQ+ communities. This included words from Acting NIH Director Larry Tabak, DDS, PhD, EDI Director Kevin Williams, Esq, NCI Director Monica Bertagnolli, MD, and NCI Executive Director Donna Siegle. A virtual and in-person panel on “Building your NIH Career with Pride” was also held and featured LGBTQ+ speakers across NIH who discussed mentoring and their career journeys.


NCI’s Office of Government and Congressional Relations (OGCR) Works with DCTD

NCI’s OGCR coordinates, monitors, and analyzes Congressional activities related to NCI and facilitates relationships between NCI and Congress. OGCR also works closely with divisions across NCI to coordinate responses to Congress, as well as with other offices at both the institute and agency levels. OGCR has a long history of working with DCTD staff across multiple projects. One recent example was on June 28, when OGCR spearheaded a visit to NCI focused on childhood cancer research with staff to Sens. Tammy Baldwin (D-WI), Shelley Moore Capito (R-WV), and Chris Van Hollen (D-MD), as well as staff to Reps. Kathy Castor (D-FL), and Mike Kelly (R-PA). The group met with NCI extramural program leaders, including DCTD staff Malcolm Smith, MD, PhD and Nita Seibel, MD, and leadership from NCI’s Pediatric Oncology Branch, and participated in two lab tours. The Congressional staff also toured the NIH Clinical Center and The Children’s Inn at NIH.

Photo of NCI Staff

NCI staff pictured standing from left to right: Dr. Michelle Mollica, Deputy Director of the NCI Office of Cancer Survivorship; Dr. Gregory Reaman, Childhood Cancer Data Initiative Scientific Director; Dr. Carol Thiele, Deputy Chief of the POB; Deputy Director for CCR; and Head, Cell and Molecular Biology Section; Dr. Nita Seibel, Head, Pediatric Solid Tumor Therapeutics, CTEP; Dr. Malcolm Smith, Associate Branch Chief for Pediatric Oncology, CTEP; Dr. Brigitte Widemann, Chief of the POB; Head, Pharmacology and Experimental Therapeutics Section; and Special Advisor on Childhood Cancer to the NCI Director

Visiting staff pictured seated from left to right: Ms. Ijeoma Egekeze (Sen. Chris Van Hollen, MD); Mr. Quinn Ritchie (Rep. Mike Kelly, PA); Ms. Maureen Szemborski, Office of the First Lady; Ms. Dana Richter (Sen. Shelly Moore Capito, WV); Ms. Kiley Mulligan (Sen. Tammy Baldwin, WI); Ms. Capreece Kelsaw (Rep. Kathy Castor, FL)

The cover art related to the paper shows the high-throughput process with a structure of a natural product in the center.

NCI Program for Natural Product Discovery Prefractionated Library Is Featured on the Cover of ACS Infectious Diseases

The National Institute of Allergy and Infectious Diseases and NCI collaborated on a project to screen more than 300,000 natural products for the potential to fight diseases. Using the NCI Program for Natural Product Discovery (NPNPD), more than 3,000 natural product fractions had possible antimicrobial/fungal activity. Read the publication.

The cover art related to the paper shows the high-throughput process with a structure of a natural product in the center. Learn more about the NPNPD, including how to request samples for your research.

Clinical Proteomic Tumor Analysis Consortium (CPTAC) Releases Proteogenomic Dataset

CPTAC released a comprehensive dataset that standardizes genomic, proteomic, imaging, and clinical data from individual studies of more than 1,000 tumors across 10 cancer types. Cancer researchers can use this publicly available resource to uncover new molecular insights into how cancers develop and progress. The dataset and examples of its potential are described in three papers published in Cell by CPTAC investigators. Read more in NCI’s media advisory “NCI unveils comprehensive proteogenomic dataset to help cancer researchers unravel molecular mysteries.” These papers were also discussed in the September 12, 2023 edition of NIH Research Matters: Advancing molecular insights into cancer.

NCI and User Access Update

To ensure the security of NCI systems, subjects, staff, and data, Identity Proofing (IP) and Multi-Factor Authentication (MFA) have been incorporated into the user access procedure. These additional security controls will better protect the integrity of all NIH systems using CTEP-IAM and/or NIH credentials. This recent change is required to meet the Presidential and Office of Management and Budget directive on improving the Nation’s cyber security. To meet this requirement, NCI has partnered with Read more details on this important update.

NIH Trial Leads to Atezolizumab Approval for Alveolar Soft Part Sarcoma (ASPS) — Data Published in New England Journal of Medicine

On December 9, 2022, the US FDA approved the immunotherapy drug atezolizumab for the treatment of alveolar soft part sarcoma (ASPS). ASPS is a rare disease affecting fewer than 100 people per year in the U.S. Alice Chen, MD, Developmental Therapeutics Clinic (DTC), led the trial that informed the FDA approval. This treatment is not only available now for adults with ASPS, but also for children 2 years and older; this represents the first FDA approval for atezolizumab in the pediatric population. NCI’s press release provides more information on the trial and results.

Dr. Alice Chen sits with one of her patients. Credit: National Cancer Institute

Since the FDA approval, the complete data from the trial were recently reported in the New England Journal of Medicine. To accompany the publication, NCI shared a short video on social media “NCI Minute: Immunotherapy for a Rare Cancer.” External Link

In reference to the ASPS trial, Dr. Chen was featured in the Community Stories section of the Childhood Cancer Data Initiative on NCI’s website.

Dr. Alice Chen sits with one of her patients. Credit: National Cancer Institute

Quantum Sensing Podcast

Jeff Buchsbaum, MD, PhD, participated in a 3-part podcast with Ecosystemic Futures. Listen to Part 1 here: Quantum Sensing — A New Era of Wicked Opportunities in Sensing External Link

Background on the podcast from Ecosystemic Futures

Quantum sensing is impacting the way we observe and analyze the world today. It measures activity in the physical world using atomic properties, resulting in the collection of extremely precise information, ultimately helping us understand the inner workings of complex systems at atomic scale. The potential implications are profound. On today’s episode of Ecosystemic Futures, our hosts sit down with Dr. Jeff Buchsbaum, a medical officer at the National Cancer Institute to discuss the applications and implication of Quantum sensing.

New on DCTD Websites

  • DCTD has a dedicated page for DCTD-supported research networks, which is located under the Research tab in the top navigation bar of the DCTD homepage.
  • DCTD recently launched a detailed webpage for the Cancer Immune Modeling and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) Network. You can find information about the network’s history, standardized assays, clinical data standardization and specimens, clinical trials collaborating with CIMAC-CIDC, and publications stemming from the network’s efforts.
  • DCTD has updated the methodology for the NCI-60 from a 96-well to a 384-well plate using a high-throughput system. September 30 was the last day to submit compounds to be screened using the traditional screen. Read more about this update.
  • A summary and all recordings from the Cancer, Aging, and Immunology webinar series are available on the DCTD Events page. Watch the webinars.

Selected Recent Publications and NCI Cancer Currents Blog Posts


Coleman CN, Wong R, Petereit DG, et al. NCI’s Cancer Disparities Research Partnership Program: A unique funding model 20 years later. J Natl Cancer Inst. 2023 Sep 14. Online ahead of print. PubMed

Chen AP, Sharon E, O’Sullivan-Coyne G, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023 Sep 7;389(10):911-921. PubMed

Dexheimer TS, Coussens NP, Silvers T, et al. Multicellular complex tumor spheroid response to DNA repair inhibitors in combination with DNA-damaging drugs. Cancer Res Commun. 2023 Aug 25;3(8):1648-1661. PubMed

Flores-Toro JA, Jagu S, Armstrong GT, et al. The Childhood Cancer Data Initiative: Using the power of data to learn from and improve outcomes for every child and young adult with pediatric cancer. J Clin Oncol. 2023 Aug 20;41(24):4045-4053. PubMed

Morris J, Kunkel MW, White SL, et al. Targeted investigational oncology agents (IOA) in the NCI60: A phenotypic systems-based resource. Mol Cancer Ther. 2023 Aug 7. Online ahead of print. PubMed

Dou Y, Katsnelson L, Gritsenko MA, et al. Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer Cell. 2023 Aug 2. Online ahead of print. PubMed

Harris LN, Blanke CD, Erba HP, et al. The new NCI precision medicine trials. Clin Cancer Res. 2023 Aug 2. Online ahead of print. PubMed

Ascierto PA, Agarwala SS, Warner AB, et al. Perspectives in melanoma: Meeting report from the Melanoma Bridge (December 1st-3rd, 2022 — Naples, Italy). J Transl Med. 2023 Jul 28;21(1):508. PubMed

Freidlin B, Korde LA, and Korn EL. Timing and reporting of secondary overall survival end points for phase III trials in advanced/metastatic disease. J Clin Oncol. 2023 Jul 20. Online ahead of print. PubMed.

O’Dwyer PJ, Gray RJ, Flaherty KT, et al. The NCI-MATCH trial: Lessons for precision oncology. Nat Med. 2023 June;29(6):1349-1357. PubMed

Kim MM, Mehta MP, Smart DK, et al. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: Challenges and recommended priorities. Lancet Oncol. 2023 Aug;24(8):e344-e354. PubMed

McCall SJ, Lubensky IA, Moskaluk CA, et al. The Cooperative Human Tissue Network of the National Cancer Institute: Supporting cancer research for 35 years. Mol Cancer Ther. 2023 Jul 28. Online ahead of print. PubMed

Some people with rectal cancer can skip radiation before surgery; Cancer Currents. July 19, 2023.


Title Announcement Number Closing Date Activity Code
Next generation chemistry centers for fusion oncoproteins (Clinical Trial Not Allowed) RFA-CA-23-037 November 16, 2023 UM1
Mechanisms of fusion-driven oncogenesis in childhood cancers (Clinical Trial Not Allowed) RFA-CA-23-036 November 16, 2023 U01
Innovative research in cancer nanotechnology (IRCN; Clinical Trial Not Allowed) PAR-23-246 May 5, 2026 R01
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (Clinical Trial Not Allowed) PAR-23-264 September 8, 2026 R01
Academic-industrial partnerships (AIP) to translate and validate in vivo imaging systems (Clinical Trial Optional) PAR-23-259 January 8, 2027 R01